Case Studies

Challenge: A biotech company developing novel gene therapy approaches for in vivo cell trans-differentiation required an AAV gene therapy expert to serve on a scientific advisory board (SAB) tasked...

Challenge: A disease area unit within a global biopharmaceutical company was charged with a mandate to seek out novel candidate assets in development to treat inflammatory bowel disease (IBD) and...

Project Challenge: A US technology transfer office required support in evaluating its life science research programs to help direct internal funding towards its most commercially viable projects....

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A venture capital portfolio company developing small molecule therapeutics for metabolic/obesity indications had made the strategic decision to supplement their internal product pipeline...

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge: A national biomedical research agency requested Alacrita’s support with (1) a technical assessment of the agency’s own internal capabilities in AAV manufacturing, (2) a global landscape of...

Challenge: A medical device company has developed a nebulizer system for pulmonary delivery that can produce droplets below 1.5µm diameter. Initial clinical evaluations of demonstrator compounds used...

Challenge: A respiratory delivery specialist company was looking at established drugs to assess the attractiveness and risks of developing inhaled or intranasal formulations of selected molecules. It...

Challenge: In preparation for fundraising, a biotech company developing a clinical stage radiolabeled peptide to diagnose pulmonary diseases required an independent valuation of its technology in...

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...